TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32744134

Group type: EXPERIMENTAL
Intervention: Goal elicitation tool (demographics questionnaire and goal elicitation worksheet)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (demographics questionnaire only)
Number of subjects: 96
Study: 35264227

Group type: EXPERIMENTAL
Intervention: Change of gloves and sterile instruments before closing the abdominal wall
Number of subjects: 12800

Group type: COMPARATOR
Intervention: No changing gloves or using separate, sterile instruments (standard practice)
Number of subjects: 12800
Study: 34860737

Group type: EXPERIMENTAL
Intervention: integrated video‐based instruction
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: integrated simulator‐based instruction
Number of subjects: 66

Group type: COMPARATOR
Intervention: video‐based procedural‐only instruction
Number of subjects: 66
Study: 34020105

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention group
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Mothers of boys
Number of subjects: 279
Study: 32615321

Group type: EXPERIMENTAL
Intervention: HDL-C levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HDL-C levels in females
Number of subjects: 80

Group type: COMPARATOR
Intervention: HDL-C levels in males
Number of subjects: 80
Study: 35312171

Group type: EXPERIMENTAL
Intervention: NUTRIOSE® (RD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 50
Study: 33334129

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 32264800

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 2058
Study: 36475905

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (3 doses of 2.7 × 10^6 PfSPZ)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study: 34027920

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Beta-Alanine (BA) supplementation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Placebo (PL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 44
Study: 32141817

Group type: EXPERIMENTAL
Intervention: 7.5 mg cholecalciferol
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1 mL normal saline (placebo)
Number of subjects: 90
Study: 36138260

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33245956

Group type: EXPERIMENTAL
Intervention: Scanning laser Doppler flowmetry (SLDF)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Unattended automated office systolic BP
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Carotid femoral pulse wave velocity
Number of subjects: 398
Study: 32182747

Group type: EXPERIMENTAL
Intervention: DHA + EPA supplementation (2.1 g/day of DHA + 240 mg/day of EPA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 34982095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32301973

Group type: EXPERIMENTAL
Intervention: Autologous ADASC implantation (G-1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Decellularized human corneal stroma (G-2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Autologous ADASCs + decellularized human corneal stroma (G-3)
Number of subjects: 14
Study: 36121656

Group type: EXPERIMENTAL
Intervention: aBWL
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: aBWL + BE
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: aBWL + SDT
Number of subjects: 382
Study: 33007492

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Bone (FFB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Autogenous Bone (AB)
Number of subjects: 15
Study: 32655006

Group type: COMPARATOR
Intervention: Hyperinsulinemic diets (EDIH quintile 5)
Number of subjects: 49317

Group type: COMPARATOR
Intervention: Proinflammatory diets (EDIP quintile 5)
Number of subjects: 49317

Group type: COMPARATOR
Intervention: EDIP
Number of subjects: 49317
Study: 35045722

Group type: EXPERIMENTAL
Intervention: DPP4 inhibition (sitagliptin) during ramipril treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aprepitant (NK1 receptor blocker) during ramipril or valsartan treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo during ramipril treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo during valsartan treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo during amlodipine treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + placebo during ramipril treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + placebo during valsartan treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + placebo during amlodipine treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + aprepitant during ramipril treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + aprepitant during valsartan treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sitagliptin + aprepitant during amlodipine treatment
Number of subjects: 106
Study: 32588274

Group type: EXPERIMENTAL
Intervention: Theory-based intervention including action planning, coping planning, and self-monitoring.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment-as-usual (standard care).
Number of subjects: 200
Study: 35292982

Group type: EXPERIMENTAL
Intervention: Piano training
Number of subjects: 134

Group type: COMPARATOR
Intervention: Musical culture/music listening group
Number of subjects: 134
Study: 32496104

Group type: EXPERIMENTAL
Intervention: Individual eye movement desensitization and reprocessing (EMDR)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group-administered stress management with a trauma focus (SMT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group-administered psychological first aid (PFA)
Number of subjects: 105
Study: 32427114

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Coaching Chatbot intervention (12 weeks) with cues and intrinsic/extrinsic rewards
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (first 4 weeks without intrinsic rewards, then same rewards as intervention from week 5 to 12)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (after 12 weeks of intervention)
Number of subjects: 106
Study: 36103557

Group type: EXPERIMENTAL
Intervention: Preterm delivery group (n = 48)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Term delivery group (n = 96)
Number of subjects: 144
Study: 33874661

Group type: EXPERIMENTAL
Intervention: parodontax Comprehensive Protection toothpaste
Number of subjects: 119

Group type: COMPARATOR
Intervention: toothpaste without sodium bicarbonate (control)
Number of subjects: 119
Study: 32511114

Group type: EXPERIMENTAL
Intervention: Instructor-led advanced cardiac life support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online advanced cardiac life support
Number of subjects: 0
Study: 35143552

Group type: EXPERIMENTAL
Intervention: Individualised Physiotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 300
Study: 35958354

Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 773

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 773

Group type: COMPARATOR
Intervention: NTD registry
Number of subjects: 773
Study: 32307650

Group type: EXPERIMENTAL
Intervention: Experimental group (EG) - intrabronchially inoculated with M. haemolytica (6.5×10^6 CFU/mL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Experimental group (EG)
Number of subjects: 14
Study: 33929627

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention-matched education control
Number of subjects: 20
Study: 32808179

Group type: EXPERIMENTAL
Intervention: 1100 ppm F toothpaste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1100 TMPnano toothpaste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1100 TMPmicro toothpaste
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 60
Study: 35522618

Group type: EXPERIMENTAL
Intervention: Leap motion control and conventional therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 33829236

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Usual hospital food
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measurement
Number of subjects: 1809
Study: 34210409

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Number of subjects: 27195

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 27195

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus Aspirin
Number of subjects: 27195

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 27195
Study: 33095139

Group type: EXPERIMENTAL
Intervention: 3 mg/kg ianalumab
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ianalumab
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 36342163

Group type: EXPERIMENTAL
Intervention: Olpasiran 10 mg every 12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg every 12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg every 12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg every 24 weeks
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 33529342

Group type: EXPERIMENTAL
Intervention: AA+ (functional amino acids: Thr, Met, Trp at 120% of requirements)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AA+
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HP (high protein)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 64

Group type: COMPARATOR
Intervention: CT (control group with sterile saline solution)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ST (saline solution containing Salmonella Typhimurium)
Number of subjects: 64
Study: 32298704

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study: 35017007

Group type: EXPERIMENTAL
Intervention: Conventional Radiation Therapy (cRT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Number of subjects: 110
Study: 34273551

Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST) / Descubriendo Soluciones Juntos (DSJ) sessions, three vs. six sessions with and without booster sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35680195

Group type: EXPERIMENTAL
Intervention: Resolute Onyx polymer‐based zotarolimus‐eluting stents (ZES)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: BioFreedom polymer‐free biolimus A9‐coated stents (DCS)
Number of subjects: 1996
Study: 34518033

Group type: EXPERIMENTAL
Intervention: Combination therapy with choline fenofibrate and statin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 127
Study: 35985854

Group type: EXPERIMENTAL
Intervention: Crown fabricated from confocal microscopy-based IOS (Group T)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Crown fabricated from dual camera triangulation-based IOS (Group I)
Number of subjects: 35
Study: 33038051

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 33125266

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 451933

Group type: EXPERIMENTAL
Intervention: IGF-1 (insulin-like growth factor 1)
Number of subjects: 451933

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a)
Number of subjects: 451933

Group type: EXPERIMENTAL
Intervention: ALT (alanine aminotransferase)
Number of subjects: 451933
Study: 35902898

Group type: EXPERIMENTAL
Intervention: TA4415V
Number of subjects: 92

Group type: COMPARATOR
Intervention: Reference trastuzumab
Number of subjects: 92
Study: 33481486

Group type: EXPERIMENTAL
Intervention: Brisk walking started 15 min after the meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Different exercise types (aerobic vs. resistance vs. combined)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Different aerobic exercise types (walking vs. cycling vs. elliptical)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30 min of brisk walking
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 45 min of brisk walking
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 and 20 min of cumulative exercise
Number of subjects: 6
Study: 32682938

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 10 mg triamcinolone acetonide + 2% lidocaine hydrochloride
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (40 mg and 10 mg)
Number of subjects: 56
Study: 35894410

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (100 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carbohydrate popsicle (100 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (fasting)
Number of subjects: 60
Study: 33247691

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation of 6,000 IU (1.8 mg RAEs) per day
Number of subjects: 32

Group type: COMPARATOR
Intervention: No vitamin A supplementation (Control)
Number of subjects: 32
Study: 34773130

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 562
Study: 33535899

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) therapy, Compex-Winplate™, 3 sessions of 15 minutes per week for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 26
Study: 32660432

Group type: EXPERIMENTAL
Intervention: HPV self-sampling arm (n = 17,997)
Number of subjects: 36390

Group type: COMPARATOR
Intervention: Pap smear arm (n = 18,393)
Number of subjects: 36390
Study: 35033049

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (brisk walking 30min/day, 4‐5days/week for 6 months)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 225
Study: 34124967

Group type: EXPERIMENTAL
Intervention: Active training group (two training sessions of 1.5-2.5 hours each)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Passive training group (two video-watching sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 27
Study: 33077241

Group type: EXPERIMENTAL
Intervention: Modified Very-Low-Energy Diet (VLED)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard Dietary Intervention (SDI)
Number of subjects: 164
Study: 36433713

Group type: EXPERIMENTAL
Intervention: danuglipron 40-120 mg BID
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study: 34863444

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32223482

Group type: EXPERIMENTAL
Intervention: Hypotonic fluid (5% dextrose in 0.45% NaCl)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Isotonic fluid (5% dextrose in 0.9% NaCl)
Number of subjects: 108
Study: 32029134

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 5806
Study: 35230245

Group type: EXPERIMENTAL
Intervention: Positive suggestions group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study: 32073511

Group type: EXPERIMENTAL
Intervention: BRAF+ status
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: WNT pathway mutations
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: BRAF pathway mutations
Number of subjects: 93
Study: 35392958

Group type: EXPERIMENTAL
Intervention: Wrapping fundus of the excluded part of the stomach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonwrapping fundus of the excluded part of the stomach
Number of subjects: 100
Study: 33741815

Group type: EXPERIMENTAL
Intervention: Upper limb therapies after stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichotomised approach for ARAT analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical techniques for ARAT analysis
Number of subjects: 0
Study: 32554999

Group type: EXPERIMENTAL
Intervention: Hip Resurfacing (HR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: 28-mm metal-on-metal Total Hip Replacement (THA)
Number of subjects: 203
Study: 35398192

Group type: EXPERIMENTAL
Intervention: Computer-assisted social skills training (ScouT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive resource activation treatment (STARK)
Number of subjects: 100
Study: 34010238

Group type: EXPERIMENTAL
Intervention: Vaginal HPV self-sampling
Number of subjects: 14765

Group type: COMPARATOR
Intervention: Cervical sampling by midwives
Number of subjects: 14765
Study: 32889091

Group type: EXPERIMENTAL
Intervention: CNN algorithm for predicting NAC response
Number of subjects: 131
Study: 33478562

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SEA)
Number of subjects: 142
Study: 36108920

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) - cycling at 70% HRPeak for 30 minutes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - leg press at 70% RM, jumping for 30 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Baseline muscle strength (LMQ, handgrip)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Baseline stair climb power (SCP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Baseline physical performance (lower PPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Post-exercise responses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall effect of acute exercise (regardless of mode)
Number of subjects: 35
Study: 33458928

Group type: EXPERIMENTAL
Intervention: Pomegranate extract nutraceutical (PE), 320 mg phenolics/day for 1 month
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pomegranate extract nutraceutical (PE)
Number of subjects: 50
Study: 33185527

Group type: EXPERIMENTAL
Intervention: Topical timolol (0.5%) cream, applied three times daily for three months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated regions
Number of subjects: 29
Study: 35296307

Group type: EXPERIMENTAL
Intervention: SOC + pharmacist-managed diabetes clinic (PMDC) group (additional 6 visits with the pharmacist within 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard of care (SOC) group (routine follow up with primary provider)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: SOC + PMDC group
Number of subjects: 86

Group type: COMPARATOR
Intervention: SOC group
Number of subjects: 86
Study: 33685928

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 32729211

Group type: EXPERIMENTAL
Intervention: Humanism and Professionalism curriculum (HP-PHO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual training in humanism and professionalism (UT)
Number of subjects: 100
Study: 35168598

Group type: EXPERIMENTAL
Intervention: Extended version of Necessary Condition Analysis (NCA)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Original version of Necessary Condition Analysis (NCA)
Number of subjects: 533
Study: 34341578

Group type: EXPERIMENTAL
Intervention: Toripalimab plus GP chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo plus GP chemotherapy
Number of subjects: 289
Study: 32204978

Group type: EXPERIMENTAL
Intervention: Curcumin group (receiving 100 mL of orange juice with 12 g of carrot and 2.5 g of turmeric after each dialysis session/week for 3 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Curcumin group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (receiving the same juice without curcumin)
Number of subjects: 31
Study: 32083522

Group type: EXPERIMENTAL
Intervention: 3 g/day of MSM for 16 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1 g/day of MSM for 16 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 34089422

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 351

Group type: COMPARATOR
Intervention: Exercise plus diet
Number of subjects: 351

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 351

Group type: COMPARATOR
Intervention: Exercise alone, diet alone, and exercise plus diet
Number of subjects: 351
Study: 32819439

Group type: EXPERIMENTAL
Intervention: Standard care plus albumin (20 g in 100 mL) every 12 h for 4 days
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Standard care plus albumin
Number of subjects: 360
Study: 35223910

Group type: EXPERIMENTAL
Intervention: Spinal morphine (SM) 0.1 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bilateral landmark‐oriented TAP block with 20 ml of 0.25% bupivacaine
Number of subjects: 114
Study: 34711232

Group type: EXPERIMENTAL
Intervention: umeclidinium/vilanterol 62.5/25 µg once daily
Number of subjects: 2425

Group type: COMPARATOR
Intervention: umeclidinium 62.5 µg once daily
Number of subjects: 2425

Group type: COMPARATOR
Intervention: salmeterol 50 µg twice daily
Number of subjects: 2425
Study: 33704597

Group type: EXPERIMENTAL
Intervention: Early angiography and revascularization with guideline‐directed medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study: 34333129

Group type: EXPERIMENTAL
Intervention: Didecyl dimethyl ammonium chloride (DDAC) bathing
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Regular cleanser/shampoo bathing
Number of subjects: 1540